Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 5 clinical trials
A Trial of SHR-1802 in Patients With Failure of Standard Treatment for Advanced Malignant Tumours

The primary purpose of this study is to see if SHR-1802 is safe and tolerable for patients with locally advanced/unresectable or metastatic malignancies that are refractory to available therapy or for which no standard therapy is available.

bone marrow procedure
measurable disease
cancer
  • 0 views
  • 19 Feb, 2024
Primary Percutaneous Pericardiotomy for Malignant Pericardial Effusion (PMAP)

Pericardial effusion is a common complication in patients with metastatic malignancy. While pericardiocentesis provide effective relieve from life-threatening situation such as cardiac tamponade, recurrence of pericardial effusion after pericardiocentesis is common.

  • 0 views
  • 19 Feb, 2024
First In Human Study With ABBV-CLS-579 When Given Alone Or In Combination With Programmed Cell Death-1 Inhibitor In Participants With Locally Advanced Or Metastatic Tumors

The purpose of this study is to see how safe and effective ABBV-CLS-579 is when used alone or in combination with programmed cell death protein-1 (PD-1) inhibitors in treating solid cancers. ABBV-CLS-579 is an investigational drug being developed for the treatment of solid tumors. The study has two arms - …

  • 0 views
  • 19 Feb, 2024
Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors

This phase I/II trial studies the side effects and best dose of avelumab with M6620 in treating patients with deoxyribonucleic acid (DNA) damage repair (DDR) deficient solid tumors that have spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). DDR deficiency refers to a …

progestin
oophorectomy
hormonal contraception
CHEK2
tumor cells
  • 0 views
  • 19 Feb, 2024
Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer

This phase II study investigates how well radium-223 works in treating patients with castration-resistant prostate cancer than has spread to the bones (bone metastases). Prostate cancer is the most common cancer in men and the second leading cause of cancer death. Furthermore, many men with notably advanced disease have been …

metastatic hormone refractory prostate cancer
castration-resistant prostate cancer
prostate carcinoma
metastasis
dna damage
  • 0 views
  • 19 Feb, 2024